Regulus Therapeutics Inc. (NASDAQ:RGLS) CFO Sells $48,782.16 in Stock

Regulus Therapeutics Inc. (NASDAQ:RGLS) CFO Crispina Calsada sold 38,716 shares of the firm’s stock in a transaction that occurred on Monday, January 13th. The stock was sold at an average price of $1.26, for a total transaction of $48,782.16. Following the sale, the chief financial officer now owns 50,566 shares of the company’s stock, valued at approximately $63,713.16. The trade was a 43.36 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Regulus Therapeutics Price Performance

NASDAQ RGLS opened at $1.27 on Thursday. The company’s 50 day moving average is $1.52 and its 200-day moving average is $1.59. Regulus Therapeutics Inc. has a 12-month low of $1.08 and a 12-month high of $3.79.

Regulus Therapeutics (NASDAQ:RGLS) last issued its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.03). On average, equities analysts expect that Regulus Therapeutics Inc. will post -0.88 EPS for the current year.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of Regulus Therapeutics in a research report on Monday, November 11th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company. According to MarketBeat.com, Regulus Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $10.80.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. NEA Management Company LLC bought a new stake in shares of Regulus Therapeutics during the third quarter valued at about $10,154,000. Point72 Asset Management L.P. bought a new stake in Regulus Therapeutics during the 3rd quarter worth approximately $1,403,000. Bank of New York Mellon Corp bought a new stake in Regulus Therapeutics during the 2nd quarter worth approximately $352,000. The Manufacturers Life Insurance Company purchased a new stake in Regulus Therapeutics in the 3rd quarter worth approximately $204,000. Finally, Tyche Wealth Partners LLC boosted its holdings in Regulus Therapeutics by 920.6% in the 3rd quarter. Tyche Wealth Partners LLC now owns 106,089 shares of the biopharmaceutical company’s stock valued at $167,000 after purchasing an additional 95,694 shares during the period. Institutional investors own 92.38% of the company’s stock.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.